ReviewInternational journal of cancer2024
State of the science and future directions for research on HIV and cancer: Summary of a joint workshop sponsored by IARC and NCI.
Review in International journal of cancer, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 19 citations in OpenAlex.
- Early antiretroviral therapy and long-term cancer risk in HIV: 9-year outcomes from the START randomized trial.BMC cancer · 2026Trial
- Cancer risks and trends between 1997 and 2018, and effects of restored immunity in people living with HIV: Results from the ANRS CO4 French hospital database on HIV.International journal of cancer · 2026Article
- Incidence of AIDS-Defining Illness by Cancer Status in an Observational Study Among Medicaid Beneficiaries Living With HIV in the United States, 2001-2015.Journal of acquired immune deficiency syndromes (1999) · 2026Observational
- Incidence of dementia after a recent cancer diagnosis among people with HIV.medRxiv : the preprint server for health sciences · 2026Article
- Social and Healthcare Disruptions Due to the COVID-19 Pandemic and Associations with Psychosocial Well-Being Among Cancer Survivors With and Without HIV: Findings from the MACS/WIHS Combined Cohort Study.AIDS and behavior · 2026Article
- HIV-Associated Lymphomas: Updates from Pathogenesis to Treatment Strategies.Current HIV research · 2026Review
- Quality improvement report: Investigating barriers in HIV testing oncology patients to optimize HIV testing practice.HIV medicine · 2025Article
- Cancer incidence in people with HIV in Italy: Comparison of the ICONA COHORT with general population data.International journal of cancer · 2025Article
- Global burden of cancer attributable to HIV: a worldwide incidence analysis.The Lancet. Global health · 2025Article
- Article
- Inequities by race and ethnicity in cancer treatment receipt among people living with HIV and cancer in the U.S. (2004-2020).BMC cancer · 2025Article
- PD-1 suppression enhances HIV reactivation and T-cell immunity via MAPK/NF-κB signaling.European journal of medical research · 2025Article
- Changes in the immune index before and after surgery in urinary malignancy patients with AIDS.Scientific reports · 2025Article
- Inequities in palliative care delivery to patients with HIV and stage IV cancers in the United States (2004-2020).JNCI cancer spectrum · 2025Article
- Excess Mortality in Persons with Concurrent HIV and Cancer Diagnoses: A Retrospective Cohort Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2024Article
- HPV-associated cancers among people living with HIV: nationwide population-based retrospective cohort study 2004-21 in Estonia.European journal of public health · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
29 authors at 17 institutions in 6 countries.
Funding
Abstract
An estimated 38 million people live with human immunodeficiency virus (HIV) worldwide and are at excess risk for multiple cancer types. Elevated cancer risks in people living with HIV (PLWH) are driven primarily by increased exposure to carcinogens, most notably oncogenic viruses acquired through shared transmission routes, plus acceleration of viral carcinogenesis by HIV-related immunosuppression. In the era of widespread antiretroviral therapy (ART), life expectancy of PLWH has increased, with cancer now a leading cause of co-morbidity and death. Furthermore, the types of cancers occurring among PLWH are shifting over time and vary in their relative burden in different parts of the world. In this context, the International Agency for Research on Cancer (IARC) and the US National Cancer Institute (NCI) convened a meeting in September 2022 of multinational and multidisciplinary experts to focus on cancer in PLWH. This report summarizes the proceedings, including a review of the state of the science of cancer descriptive epidemiology, etiology, molecular tumor characterization, primary and secondary prevention, treatment disparities and survival in PLWH around the world. A consensus of key research priorities and recommendations in these domains is also presented.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.